Navigation Links
FDA Clears ExAblate Fertility Enhancement Study in Women With Uterine Fibroids
Date:5/28/2008

istration in 2004 as a treatment for symptomatic uterine fibroids, ExAblate has been recognized for its innovation and potential to serve mankind and has been awarded the 2004 European Union's Information Society Technologies grand prize, The Wall Street Journal's 2004 Technology Innovation Awards, Advanced Imaging's 2005 Solutions of the Year, the Red Herring 100 Europe 2007 Award and currently one of the World Economic Forum Technology Pioneer 2008.

About InSightec

InSightec Ltd. is a privately held company owned by Elbit Imaging (EI), General Electric, MediTech Advisors, LLC and employees. It was founded in 1999 to develop the breakthrough MR guided Focused Ultrasound technology and transform it into the next generation operating room. Headquartered near Haifa, Israel, the company has over 160 employees and has invested more than $100 million in research, development, and clinical investigations. Its U.S. headquarters are located in Dallas, Texas. For more information, please go to: http://www.insightec.com/

Media Contact

Hollister Hovey

Lazar Partners Ltd.

+1-646-871-8482


'/>"/>
SOURCE InSightec Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer
2. American Fertility Association Calls for Expanded Research to Advance New Technology to Screen Embryos for Genetic Abnormalities
3. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
4. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
5. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
6. First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer
7. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
8. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
9. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
10. Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
11. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Helix BioPharma Reports On 2009 Annual General Meeting 2Helix BioPharma Reports On 2009 Annual General Meeting 3NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 2Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 3Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 4Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 5Undocumented Hispanics Face Health Care Roadblocks in U S 60405 1Undocumented Hispanics Face Health Care Roadblocks in U S 60405 2U S President 26apos 3Bs Emergency Plan for AIDS Relief Joins mHealth Alliance 60401 1U S President 26apos 3Bs Emergency Plan for AIDS Relief Joins mHealth Alliance 60401 2U S President 26apos 3Bs Emergency Plan for AIDS Relief Joins mHealth Alliance 60401 3Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival 14666 1Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival 14666 2Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival 14666 3Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival 14666 4